Category: News & Comments

The FDA Granted Novartis a Historical First CAR-T Approval for Leukemia. Can You Guess Who Will Be Granted the Second Historical CAR-T Approval?

The answer is, indeed, Gilead (GILD) and its CAR T drug approval will be for non-Hodgkin lymphoma (NHL). This is true, as in May, the FDA has accepted for priority review Kite Pharma’s Biologics License Application (BLA) for its genetically...

Read More

August 31, 2017

0

Sangamo's stock price Soars 52% in pre-market hours on hemophilia A trial results

Sangamo's Stock Price Soars Sangamo Therapeutics' ( SGMO ) stock soared more than 52% in pre-market trading following the announcement with Pfizer ( PFE ), of interim data from Phase 1/2 Alta study evaluating the firm’s gene therapy product SB-525...

Read More

April 2, 2019

0

The medical news of the year comes at the hands of Abott

While preparing The Week in Review issue from Prohost, our attention  shifted towards historical news about a procedure that improved the heart function in severe heart failure patients . For cardiologists and their patients, the positive results were surprising, stunning...

Read More

September 24, 2018

0

About Portola's Conference Call Today

Portola Portola Pharmaceuticals (PTLA) announced that it will host a webcast and conference call to provide an update on its anticoagulant Factor Xa inhibitor Bevyxxa ®  (betrixaban) launch plans, the validation of the commercial manufacturing process and drug release timing. Conference...

Read More

September 5, 2017

0

Regeneron and Alnylam collaborative agreement will benefit these firms so why the selloff of both?

Regeneron and Alnylam Agreement Will Benefit Both So Why the Sell-Off? Regeneron Pharmacueticals Founded, and led for 30 years, by physician-scientists   Regeneron Pharmaceuticals ( REGN ) demonstrates an exceptional ability to translate science into medicine. Working diligently Regeneron succeeded...

Read More

April 9, 2019

0

Antisense investigational product demonstrates successful results treating a life-threatening disease with no current treatment

The high risk of premature death from cardiovascular disease is believed to be caused by an elevated level of lipoprotein (a) {Lp(a)} . Elevated Lp(a) is described as an independent, hereditary risk factor for cardiovascular disease (CVD). Diet and exercise,...

Read More

September 27, 2018

0

NewLink Genetics: A Rally is Recuperating NLNK's Unwarranted Stock Losses

Indeed, updated data from the ongoing Phase 2 NLG2103 study of NewLink Genetics (NLNK) IDO inhibitor immunotherapy product indoximod in combination with the PD-1 pathway inhibitor, KEYTRUDA (pembrolizumab) demonstrate positive results in advanced melanoma. The news rallied the stock that...

Read More

September 8, 2017

0

Amicus' Drug Failed! Why Investors Are Not Abandoning Ship

Amicus (FOLD) announced the failure of its topical wound-healing product SD-101 for patients with epidermolysis bullosa (EB). The drug failure was revealed when top-line results from the randomized, double-blind, placebo-controlled Phase 3 clinical ESSENCE study SD-101 were announced. The results...

Read More

September 13, 2017

0

Gilead and insitro announce strategic collaboration to discover and develop novel therapies for NASH

Gilead and insitro Collaborate to Discover and Develop Novel Therapies for NASH using ISH Gilead Sciences ( GILD )   and insitro  entered into a strategic collaboration to discover and develop treatments for nonalcoholic steatohepatitis (NASH) . NASH A chronic...

Read More

April 16, 2019

0

The FDA granted Paratek two important product approvals. One is for acne

The U.S. Food and Drug Administration (FDA) has approved Paratek Pharmaceuticals' (PRTK)  product Seysara™ (sarecycline)  for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Paratek has exclusively licensed U.S. development and commercialization rights...

Read More

October 3, 2018

0

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0